Sign in
DGCRF Stock Price, Chart, Stats & News
Diagnocure, Inc.
Save
Diagnocure, Inc. (DGCRF) does not currently pay a dividend.
21,520
Market cap
–
Current P/E
–
Forward P/E
DGCRF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Medical - Specialties
Industry
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer.
Similar securities
Based on sector and market capitalization
Report issue